Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Input: Consider Input: To study the mechanism of centrosome duplication in cycling cells, we established a novel system of multiple centrosome formation in two types of cells: CHO cells treated with RO3306, a Cyclin-dependent kinase 1 (Cdk1) inhibitor and DT40 cells, in which Cdks were knocked out by chemical genetics. Cdk1-inactivated cells initiated DNA replication and centrosome duplication at the onset of S phase. They became arrested at the end of G2, but the centrosome cycle continued to produce supernumerary centrioles/centrosomes without DNA endoreplication in those cells. Centrosomes were amplified in a highly synchronous and reproducible manner: all of them were located next to the nucleus and spread widely apart from each other with several m in distance. Double knockout of Cdk1 and Cdk2 caused cell cycle arrest at G1/S and centrosomes were no longer duplicated. However, cells continued to grow and increased their volume over 10-fold during 48 hr of culture. Centrosome components, including -tubulin and Cep135, were synthesized and accumulated during the arrest, allowing rapid centrosome multiplication upon recovery from the cell cycle arrest or expression of exogenous Plk4 in G1/S cells. Thus centrosome amplification results from the discoordination of the centrosome cycle from the progression of other cell cycle events, which is controlled by different levels of Cdk activities.

Output: Where in the cell do we find the protein Cep135?

Input: Consider Input: The aim of this study was to elucidate the role of lysyl oxidase (LOX) and lysyl oxidase like (LOXL) 2 in pathologic wound healing after glaucoma surgery. We therefore investigated the expression of LOX and LOXL2 and evaluated the therapeutic potential of anti-LOX (GS-639556, formerly M64) and anti-LOXL2 (GS-607601, formerly AB0023) antibodies in a rabbit model of glaucoma trabeculectomy. Ocular expression of LOX and LOXL2 was investigated by immunohistologic staining at different time points after trabeculectomy. Treatment with GS-639556 or GS-607601 was initiated in rabbits immediately after trabeculectomy by giving both intracameral and subconjunctival injections. Thereafter, the antibodies were given twice a week subconjunctivally until day 30 after surgery (day of euthanization). Treatment outcome was studied by clinical investigation of the bleb and by immunohistochemical analysis of angiogenesis, inflammation, and collagen deposition. LOX and LOXL2 were both upregulated in Tenon's capsule and the conjunctiva after glaucoma surgery. Repeated administration of LOX- or LOXL2-targeting monoclonal antibodies increased bleb area and bleb survival. Analyses of immunohistologic stainings showed that both antibodies significantly decreased fibrosis, whereas the anti-LOXL2 antibody also significantly reduced blood vessel density and inflammation. Targeting LOXL2 with an inhibitory monoclonal antibody (GS-607601) reduced pathologic angiogenesis, inflammation, and fibrosis. These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.

Output: What is the drug target for Simtuzumab?

Input: Consider Input: It was 1:30 a.m. Monday at London's Savoy Hotel and, with autograph books and cameras, a group of brighteyed tennis fans of all ages were waiting for just a glimpse of Maria Sharapova . The 17-year-old girl defeated champion Serena Williams 6-1 6-4 in the Wimbledon final on Saturday in London to become the first Russian to win a single title at the championships. A silver lining to a depressing, rain-hit Wimbledon, she has raised heated passion. Nobody was complaining, though, for the 1.83-metre Sharapova has created a welcome wave of interest in tennis, something missing in recent years. Not even Anna Kournikova evoked such passion when she broke on to the scene. To look good on court is one thing, but Sharapova can actually play the game too. Extremely well. She proved it over 13 days at the world's most prestigious tournament. Playing tennis of the highest quality throughout, the Russian's triumph not only lifted the tournament from fits of rain-induced depression but also salvaged(;) the season for the woman's tour. Sharapova was given no easy ride in the tournament, having to beat 1999 champion Lindsay Davenport in the semifinals and twice-champion Serena Williams for the title. Neither caused her much concern. "I don't remember too much about the final," Sharapova giggled. "I was in my own place." She will find it increasingly hard to find any place to call her own from now on after advertisers identified her as the most marketable woman in sport. In Russia she is sensational news. She headlined the news bulletins and was telephoned by former Russian President Boris Yeltsin after her triumph. Sharapova will return to her adoptive Florida home knowing life will never be the same again. But the girl who arrived in the US aged seven with her father and just US$700 is determined not to let fame and riches detract from her number one love, tennis. "I know things will start coming up and that many more things will want to get involved, but I want to keep my head cool and play tennis," she said.
Output: Who has won the most times in Wimbledon?